Studies on the treatment of melanoma with folate acid conjugated dextran and lauryl alcohol loaded with IMD0354

Can Liu, Wei Chen, Zizi Chen, Yu Yan, Qing Wang, Huiqing Xie, Xiang Chen, Aijun Wang, Shijie Tang, Jianda Zhou

Research output: Contribution to journalArticle

Abstract

Background: IMD-0354 is a kind of hydrophobic small molecule inhibitor of IKKβ, which can effectively inhibit the NF-κB pathway. Besides, IMD-0354 can inhibit a variety of tumor cells in culture, but its poor water solubility and low utilization have limited its clinical application. Methods: In this study, IMD-0354 was synthesized through esterifying the folate acid (FA) conjugated dextran (Dex) as well as the lauryl alcohol (LA). Results:The particle (IMD/FA-Dex-LA) size was 212.13±10.62nm, the encapsulation efficiency was 89.27±6.51%, and the drug loading was 4.25±0.42%. Cell viability studies indicated that the IMD/FA-Dex-LA effectively inhibited survival of B16F10 cells in culture. Meanwhile, Western Blotting results showed that the nuclear transport of NF-κB was reduced after blocking the IKK pathway, which would thereby suppress melanoma cell division and proliferation. Moreover, subcutaneous tumor implantation experiment revealed that, the drug-loading complex had an obvious effect on suppressing melanoma cells. Findings of this study demonstrated that the IMD-0354 loaded FA-Dex-LA was more effective than IMD-0354 alone. Conclusion: In summary, FA-Dex-LA has been successfully synthesized in this study, which can serve as a carrier for hydrophobic drug. Further, it is believed the FA-Dex-LA can potentially applied in cancer treatment.

Original languageEnglish (US)
Pages (from-to)4655-4663
Number of pages9
JournalOncoTargets and Therapy
Volume12
DOIs
StatePublished - Jan 1 2019

Fingerprint

Dodecanol
Dextrans
Folic Acid
Melanoma
Acids
Therapeutics
Cell Culture Techniques
Neoplasms
Drug Carriers
Cell Nucleus Active Transport
Pharmaceutical Preparations
Cell Division
Solubility
N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide
Cell Survival
Western Blotting
Cell Proliferation
Water

Keywords

  • Dextran
  • Folate acid
  • IKK inhibitor
  • Lauryl alcohol
  • Melanoma

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Studies on the treatment of melanoma with folate acid conjugated dextran and lauryl alcohol loaded with IMD0354. / Liu, Can; Chen, Wei; Chen, Zizi; Yan, Yu; Wang, Qing; Xie, Huiqing; Chen, Xiang; Wang, Aijun; Tang, Shijie; Zhou, Jianda.

In: OncoTargets and Therapy, Vol. 12, 01.01.2019, p. 4655-4663.

Research output: Contribution to journalArticle

Liu, Can ; Chen, Wei ; Chen, Zizi ; Yan, Yu ; Wang, Qing ; Xie, Huiqing ; Chen, Xiang ; Wang, Aijun ; Tang, Shijie ; Zhou, Jianda. / Studies on the treatment of melanoma with folate acid conjugated dextran and lauryl alcohol loaded with IMD0354. In: OncoTargets and Therapy. 2019 ; Vol. 12. pp. 4655-4663.
@article{31be584c46eb43a0b4299a2b907fa583,
title = "Studies on the treatment of melanoma with folate acid conjugated dextran and lauryl alcohol loaded with IMD0354",
abstract = "Background: IMD-0354 is a kind of hydrophobic small molecule inhibitor of IKKβ, which can effectively inhibit the NF-κB pathway. Besides, IMD-0354 can inhibit a variety of tumor cells in culture, but its poor water solubility and low utilization have limited its clinical application. Methods: In this study, IMD-0354 was synthesized through esterifying the folate acid (FA) conjugated dextran (Dex) as well as the lauryl alcohol (LA). Results:The particle (IMD/FA-Dex-LA) size was 212.13±10.62nm, the encapsulation efficiency was 89.27±6.51{\%}, and the drug loading was 4.25±0.42{\%}. Cell viability studies indicated that the IMD/FA-Dex-LA effectively inhibited survival of B16F10 cells in culture. Meanwhile, Western Blotting results showed that the nuclear transport of NF-κB was reduced after blocking the IKK pathway, which would thereby suppress melanoma cell division and proliferation. Moreover, subcutaneous tumor implantation experiment revealed that, the drug-loading complex had an obvious effect on suppressing melanoma cells. Findings of this study demonstrated that the IMD-0354 loaded FA-Dex-LA was more effective than IMD-0354 alone. Conclusion: In summary, FA-Dex-LA has been successfully synthesized in this study, which can serve as a carrier for hydrophobic drug. Further, it is believed the FA-Dex-LA can potentially applied in cancer treatment.",
keywords = "Dextran, Folate acid, IKK inhibitor, Lauryl alcohol, Melanoma",
author = "Can Liu and Wei Chen and Zizi Chen and Yu Yan and Qing Wang and Huiqing Xie and Xiang Chen and Aijun Wang and Shijie Tang and Jianda Zhou",
year = "2019",
month = "1",
day = "1",
doi = "10.2147/OTT.S207685",
language = "English (US)",
volume = "12",
pages = "4655--4663",
journal = "OncoTargets and Therapy",
issn = "1178-6930",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Studies on the treatment of melanoma with folate acid conjugated dextran and lauryl alcohol loaded with IMD0354

AU - Liu, Can

AU - Chen, Wei

AU - Chen, Zizi

AU - Yan, Yu

AU - Wang, Qing

AU - Xie, Huiqing

AU - Chen, Xiang

AU - Wang, Aijun

AU - Tang, Shijie

AU - Zhou, Jianda

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: IMD-0354 is a kind of hydrophobic small molecule inhibitor of IKKβ, which can effectively inhibit the NF-κB pathway. Besides, IMD-0354 can inhibit a variety of tumor cells in culture, but its poor water solubility and low utilization have limited its clinical application. Methods: In this study, IMD-0354 was synthesized through esterifying the folate acid (FA) conjugated dextran (Dex) as well as the lauryl alcohol (LA). Results:The particle (IMD/FA-Dex-LA) size was 212.13±10.62nm, the encapsulation efficiency was 89.27±6.51%, and the drug loading was 4.25±0.42%. Cell viability studies indicated that the IMD/FA-Dex-LA effectively inhibited survival of B16F10 cells in culture. Meanwhile, Western Blotting results showed that the nuclear transport of NF-κB was reduced after blocking the IKK pathway, which would thereby suppress melanoma cell division and proliferation. Moreover, subcutaneous tumor implantation experiment revealed that, the drug-loading complex had an obvious effect on suppressing melanoma cells. Findings of this study demonstrated that the IMD-0354 loaded FA-Dex-LA was more effective than IMD-0354 alone. Conclusion: In summary, FA-Dex-LA has been successfully synthesized in this study, which can serve as a carrier for hydrophobic drug. Further, it is believed the FA-Dex-LA can potentially applied in cancer treatment.

AB - Background: IMD-0354 is a kind of hydrophobic small molecule inhibitor of IKKβ, which can effectively inhibit the NF-κB pathway. Besides, IMD-0354 can inhibit a variety of tumor cells in culture, but its poor water solubility and low utilization have limited its clinical application. Methods: In this study, IMD-0354 was synthesized through esterifying the folate acid (FA) conjugated dextran (Dex) as well as the lauryl alcohol (LA). Results:The particle (IMD/FA-Dex-LA) size was 212.13±10.62nm, the encapsulation efficiency was 89.27±6.51%, and the drug loading was 4.25±0.42%. Cell viability studies indicated that the IMD/FA-Dex-LA effectively inhibited survival of B16F10 cells in culture. Meanwhile, Western Blotting results showed that the nuclear transport of NF-κB was reduced after blocking the IKK pathway, which would thereby suppress melanoma cell division and proliferation. Moreover, subcutaneous tumor implantation experiment revealed that, the drug-loading complex had an obvious effect on suppressing melanoma cells. Findings of this study demonstrated that the IMD-0354 loaded FA-Dex-LA was more effective than IMD-0354 alone. Conclusion: In summary, FA-Dex-LA has been successfully synthesized in this study, which can serve as a carrier for hydrophobic drug. Further, it is believed the FA-Dex-LA can potentially applied in cancer treatment.

KW - Dextran

KW - Folate acid

KW - IKK inhibitor

KW - Lauryl alcohol

KW - Melanoma

UR - http://www.scopus.com/inward/record.url?scp=85069850363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069850363&partnerID=8YFLogxK

U2 - 10.2147/OTT.S207685

DO - 10.2147/OTT.S207685

M3 - Article

AN - SCOPUS:85069850363

VL - 12

SP - 4655

EP - 4663

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

SN - 1178-6930

ER -